MAM
RYTM icon

Meeder Asset Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Meeder Asset Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-82
Closed -$4.3K – 1004
2024
Q3 		$4.3K Buy
+82
New +$3.93K ﹤0.01% 768
2021
Q3 		– Sell
-6,078
Closed -$119K – 2611
2021
Q2 		$119K Buy
+6,078
New +$126K 0.01% 856
2020
Q4 		– Sell
-9,824
Closed -$213K – 2166
2020
Q3 		$213K Buy
9,824
+9,529
+3,230% +$218K 0.01% 594
2020
Q2 		$7K Sell
295
-359
-55% -$7K ﹤0.01% 1434
2020
Q1 		$10K Buy
654
+293
+81% +$5.25K ﹤0.01% 1524
2019
Q4 		$8K Buy
+361
New +$8.02K ﹤0.01% 1640
2019
Q3 		– Sell
-76
Closed -$2K – 2252
2019
Q2 		$2K Buy
+76
New +$1.92K ﹤0.01% 1877
2019
Q1 		– Sell
-583
Closed -$16K – 1829
2018
Q4 		$16K Sell
583
-83
-12% -$2.29K ﹤0.01% 1125
2018
Q3 		$19K Buy
666
+460
+223% +$14.5K ﹤0.01% 1042
2018
Q2 		$6.44K Buy
+206
New +$5.63K ﹤0.01% 1211
2018
Q1 		– Sell
-225
Closed -$6K – 1723
2017
Q4 		$6K Buy
+225
New +$5.95K ﹤0.01% 1272

Other funds holding RYTM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Meeder Asset Management's RYTM Position: Q4 2024 in Review

Meeder Asset Management sold out of Rhythm Pharmaceuticals (RYTM) in Q4 2024, closing a stake of 82 shares — an estimated $4.3K sold.

Meeder Asset Management first reported a position in RYTM in Q4 2017 and held it in 11 quarters. The position peaked at $213K in Q3 2020. 203 funds tracked by Wall St. Rank hold RYTM as of Q4 2024.

  • Meeder Asset Management reported no remaining Rhythm Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Meeder Asset Management sold 82 Rhythm Pharmaceuticals shares in Q4 2024, an estimated $4.3K.
  • Meeder Asset Management first reported a position in Rhythm Pharmaceuticals in Q4 2017 and held it in 11 quarters.
  • Meeder Asset Management's Rhythm Pharmaceuticals position peaked at $213K in Q3 2020.
  • 203 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q4 2024.

Based on Meeder Asset Management's 13F filing for Q4 2024, filed 12 Feb 2025.